KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Non-Current Debt (2016 - 2025)

Boston Scientific's Non-Current Debt history spans 17 years, with the latest figure at $11.1 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 24.19% year-over-year to $11.1 billion; the TTM value through Dec 2025 reached $11.1 billion, up 24.19%, while the annual FY2025 figure was $11.1 billion, 24.19% up from the prior year.
  • Non-Current Debt for Q4 2025 was $11.1 billion at Boston Scientific, up from $9.0 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $11.1 billion in Q4 2025 and bottomed at $8.4 billion in Q3 2023.
  • The 5-year median for Non-Current Debt is $8.8 billion (2021), against an average of $9.0 billion.
  • The largest annual shift saw Non-Current Debt fell 4.65% in 2021 before it increased 24.19% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $8.8 billion in 2021, then increased by 1.26% to $8.9 billion in 2022, then decreased by 3.86% to $8.6 billion in 2023, then increased by 4.63% to $9.0 billion in 2024, then increased by 24.19% to $11.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Non-Current Debt are $11.1 billion (Q4 2025), $9.0 billion (Q4 2024), and $9.0 billion (Q2 2024).